Product Pipeline Business Development

About Us



» Corporate Strategy



» Management Team



» Board of Directors






Board of Directors

Neil Flanzraich
Executive Chairman

Mr. Flanzraich is the Executive Chairman of Kirax Corporation. Also, Mr. Flanzraich is the Chairman of ParinGenix, Inc., another privately owned biotech company, which is developing a unique anti-inflammatory agent for a number of indications. Additionally, Mr. Flanzraich is a founder and a principal of a venture capital firm named Leviathan Biopharma Group, LLC.

Mr. Flanzraich was the Vice Chairman and President of Ivax Corporation, an international pharmaceutical company, that was sold to Teva in 2006 for $10 billion. Earlier he was the Senior Vice President and Chief Counsel and a member of the Executive Committee of Syntex Corporation, an international pharmaceutical company, that was sold to Roche in 1994 for $5.3 billion. He was also the Chairman of North American Vaccine, Inc., that was sold in 2000 to Baxter International, Inc. for about $500 million.

Currently, Mr. Flanzraich is also member of the boards of directors of the following public companies: Bellus Health Inc., Chipotle Mexican Grill, Continucare Corporation, and Equity One, Inc. Additionally, he is a member of the Board of Directors of privately-owned Outcomes Health Information Solutions, LLC, a provider of healthcare data retrieval, analytics and management services. Mr. Flanzraich is also a member of the Advisory Board of The Wolfsonian-FIU, a museum of art, design and communication.

Mr. Flanzraich graduated from Harvard College (magna cum laude, Phi Beta Kappa) and from Harvard Law School (magna cum laude). He is married and has two sons.



Edmundo Muniz, M.D., Ph.D.
President and Chief Executive Officer

Dr. Muniz brings over 22 years of drug development experience in oncology, Cardiovascular, and infectious disease. Prior to joining Kirax, Dr. Muniz was Vice President for Lilly Research Laboratories Global Oncology Platform at Eli Lilly and Company. At Lilly, Dr. Muniz was responsible for Phase II, III and IV clinical trials for oncology compounds worldwide and for Global Marketing Pre-launch.

Under Dr. Muniz's leadership, Lilly Oncology achieved 9 major oncology submissions worldwide, with all 9 of those already having gained approval in the US, Europe and Japan. Such projects include Dr. Muniz's extensive involvement in the development of approved oncology therapeutics Alimta® and Gemzar®. Additionally, Dr. Muniz led the launch of Lilly Oncology on Canvas: Expressions of a Woman's Cancer Journey, an international art exhibition that displays works from over 400 cancer survivors, family members, care providers and friends. Prior to joining Eli Lilly, Dr. Muniz completed a PhD in Epidemiology and International Health at the University of Michigan and later completed a residency in Preventive Medicine and a Fellowship in Epidemic Intelligence with the Centers for Disease Control and Prevention (CDC) in Atlanta.


Joshua A. Kazam
Secretary and Director

Mr. Kazam, a co-founder of Kirax (formerly Tigris), currently serves as the Secretary and a member of the Board of Directors of the Company. Mr. Kazam co-founded Two River Group Holdings, LLC in September 2004.

Prior to that, from September 1999, Mr. Kazam served as a Managing Director of Paramount BioCapital, Inc. He also served as Managing Director of Paramount BioCapital Investments, LLC, where he was responsible for ongoing operations of venture investments. In addition, Mr. Kazam served as the Director of Investment for the Orion Biomedical Fund, a New York based private equity fund focused on biotechnology investments. Mr. Kazam also currently serves as a director of Manhattan Pharmaceuticals, Inc. (AMEX:MHA), a publicly traded biotechnology company, as well as several privately held companies, including Cortiva Therapy and Velcera Pharmaceuticals, Inc., a privately held veterinary company.

Mr. Kazam graduated with honors from the Wharton School of the University of Pennsylvania with a degree in management. Mr. Kazam will devote only a portion of his business time to the Company's business.



Peter M. Kash
Director

Peter M. Kash has served as a director of the Company since its inception. In September 2004, Mr. Kash co-founded Two River Group Holdings, LLC, a venture capital firm that specializes in the creation of new companies to acquire rights to commercially develop early stage biotechnology products. He serves as President of Two River Group Management, LLC, the managing member of Two River Group Holdings, LLC. Mr. Kash is also the President and Chairman of Riverbank Capital Securities, Inc., a broker-dealer registered with the Financial Industry Regulatory Authority, or FINRA (formerly NASD). From 1992 until 2004, Mr. Kash was a Senior Managing Director of Paramount BioCapital, Inc., a FINRA member broker-dealer, specializing in conducting private financings for public and private development stage biotechnology companies as well as Paramount BioCapital Investments, LLC, a venture capital company. Mr. Kash also served as Director of Paramount Capital Asset Management, Inc., the general partner of several biotechnology-related hedge funds and as member of the General Partner of the Orion Biomedical Fund, LP, a private equity fund. Mr. Kash received his B.S. in Management Science from SUNY Binghamton and his M.B.A. in Banking and International Finance from Pace University. Mr. Kash is currently completing his doctorate in education at Yeshiva University.